Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda.
Department of Pathology, Johns Hopkins University, Baltimore, MD.
Am J Surg Pathol. 2018 Oct;42(10):1306-1316. doi: 10.1097/PAS.0000000000001113.
Traditionally low-grade B-cell lymphomas have been excluded from the category of monomorphic posttransplant lymphoproliferative disorders. However, recent reports identified Epstein-Barr virus-positive (EBV) extranodal marginal zone lymphomas (MZL), almost exclusively seen in the posttransplant setting. Some reported cases responded to reduced immunosuppression, suggesting that they should be considered as a form of posttransplant lymphoproliferative disorders. We identified 10 cases of EBV MZL, 9 in extranodal sites and 1 presenting in lymph node. Two cases arose following solid organ transplantation, but other settings included iatrogenic immunosuppression for rheumatoid arthritis (2); prior chemotherapy (2); congenital immune deficiency (1); and increased age (3), as the only potential cause of immune dysfunction. There were 4 males and 6 females; age range 18 to 86. The atypical plasmacytoid and/or monocytoid B cells were positive for EBV in all cases, with either latency I or II in all cases tested. Monotypic light chain expression was shown in all with 6 cases positive for IgG, and 2 for IgM, undetermined in 2. Clonal immunoglobulin gene rearrangement was positive in all cases with successful amplification. MYD88 L265P was wild type in the 6 cases tested. We show that EBV MZLs can arise in a variety of clinical settings, and are most often extranodal. Treatment varied, but most patients had clinically indolent disease with response to reduction of immune suppression, or immunochemotherapy.
传统上,低度 B 细胞淋巴瘤已被排除在单形性移植后淋巴组织增生性疾病的范畴之外。然而,最近的报告确定了 EBV 阳性(EBV)结外边缘区淋巴瘤(MZL),这种疾病几乎只发生在移植后。一些报道的病例对减少免疫抑制有反应,这表明它们应被视为移植后淋巴组织增生性疾病的一种形式。我们鉴定了 10 例 EBV MZL,9 例发生在结外部位,1 例发生在淋巴结。其中 2 例发生在实体器官移植后,但其他发病情况包括类风湿关节炎的医源性免疫抑制(2);先前的化疗(2);先天性免疫缺陷(1);和年龄增长(3),这是唯一潜在的免疫功能障碍原因。有 4 名男性和 6 名女性;年龄范围为 18 至 86 岁。所有病例的非典型浆母细胞和/或单核样 B 细胞均为 EBV 阳性,所有检测病例均为潜伏 I 或 II。所有病例均显示单型轻链表达,6 例 IgG 阳性,2 例 IgM 阳性,2 例未确定。所有病例的克隆免疫球蛋白基因重排均为阳性,且成功扩增。在 6 例检测的病例中,MYD88 L265P 均为野生型。我们表明,EBV MZL 可发生在多种临床情况下,且通常为结外部位。治疗方法各不相同,但大多数患者的疾病具有临床惰性,对减少免疫抑制或免疫化疗有反应。